Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Glioblastoma

Moving forward with combined forces

    • Neurology
    • News
    • Oncology
    • RX
    • Studies
  • 2 minute read

Considering that glioblastomas are among the most common and malignant brain tumors and have a very poor prognosis, optimizations of the current therapy are urgently needed. Two publications are attracting attention in this regard: one tested the addition of bevacizumab to standard chemoradiotherapy, the other used methadone to enhance the effect of chemotherapy.

(ag) Bevacizumab is indicated as monotherapy for the treatment of patients with recurrent glioblastoma (WHO grade IV) after prior therapy with temozolomide. However, radiotherapy plus temozolomide remains the standard of care in primary treatment, so a new phase III trial [1] tested the extent to which the addition of bevacizumab could improve treatment success in this population as well.

The total of 921 patients with newly diagnosed glioblastoma received either intravenous bevacizumab (n=458) or placebo (n=463) in addition to standard therapy. After treatment was stopped on day 28, six months of maintenance therapy with bevacizumab/placebo plus temozolomide was started. This was followed by the monotherapy phase with bevacizumab/placebo until progression or unsustainable toxicities.

No benefit in overall survival

While one of the co-primary endpoints, progression-free survival, showed a significant benefit of addition across all subgroups (10.6 vs. 6.2 months, HR 0.64, p<0.001), overall survival did not differ significantly (HR 0.88, p=0.1).

Regarding the secondary endpoints: Survival rates at one year were 72.4 with bevacizumab and 66.3% with placebo (p=0.049), and 33.9 and 30.1% at two years (p=0.24). More adverse events of grade three or higher occurred in the bevacizumab group.

Thus, although the addition significantly improved progression-free survival and did not negatively affect quality of life until progression, the increased side effects should be factored into the assessment, the authors concluded.

Methadone enhances the success of chemotherapy

A German report [2] in the field of glioblastoma also raises eyebrows: Glioblastoma cells have opioid receptors on their surface. After it was discovered that cAMP is crucial for proliferation, differentiation and apoptosis in certain tumors and that its downregulation (e.g. by means of opioid receptor agonists) could make the tumors more sensitive to anticancer treatments, this fact could now be demonstrated for the first time in glioblastomas. Specifically, methadone sensitizes glioblastomas and otherwise untreatable glioblastoma stem cells to doxorubicin-induced apoptosis. It increases doxorubicin uptake and decreases efflux (which is why smaller amounts of the cytostatic drug are needed and side effects are reduced). Friesen et al. were also able to show that doxorubicin increases the number of opioid receptors in the cancer cell, which in turn allows more methadone to bind in an escalating process.

Doxorubicin has already demonstrated efficacy in the treatment of malignant gliomas in in vitro and in vivo studies [3].

The authors conclude that opioid receptor activation may be a promising strategy to prevent tumor growth (via regulation of cAMP) and increase the efficacy of anticancer agents in the treatment of glioblastoma. Clinical studies in this direction are being planned.

Literature:

  1. Chinot OL, et al: N Engl J Med 2014; 370(8): 709-722.
  2. Friesen C, et al: Cell Cycle 2014; 13(10): 1560-1570.
  3. Fabel K, et al: Cancer 2001 Oct 1; 92(7): 1936-1942.

 

InFo ONCOLOGY & HEMATOLOGY 2014; 2(9): 6.

Autoren
  • Andreas Grossmann
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • bevacizumab
  • Brain tumor
  • Doxorubicin
  • Glioblastomas
  • Methadone
  • Toxicity
Previous Article
  • The Anemic Elderly Patient in Family Practice

What should be considered?

  • Education
  • Geriatrics
  • Hematology
  • Nutrition
  • RX
View Post
Next Article
  • Crucial for the course and prognosis of psychotic disorders

Early detection of psychosis – what the family doctor needs to know

  • Education
  • Psychiatry and psychotherapy
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
View Post
  • 4 min
  • Plea for sex-specific neurology

Migraine in men: underdiagnosed, underestimated, under-researched

    • Education
    • Neurology
    • RX
    • Studies
View Post
  • 4 min
  • Prurigo nodularis

Retrospective analyses of large data sets from everyday practice

    • Allergology and clinical immunology
    • Congress Reports
    • Dermatology and venereology
    • RX
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.